In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Licensing Vivitrex: A Win for the Mid-sized Pharma and Specialists

Executive Summary

Cephalon's acquisition of US rights to Alkermes' Vivitrex, a long-acting formulation of the alcohol abuse drug naltrexone, is a clear sign that mid-sized companies with marketed products can--thanks to their significant cash flows--contend with Big Pharma for important specialist products.

You may also be interested in...



Reformulation has Ruled in Neurology Dealmaking--Until Now

The big deals in other therapeutic areas focus on novel molecules, in neurology, most focus on formulations of existing molecules. There just hasn't been a lot of novel material that's piqued the interest of licensees, at least in part because of the risk of developing novel neurology compounds. But as Windhover's Therapeutic Alliances: Neuroscience conference showed, much of the new, licensable pipeline is very novel indeed.

The Rise of Regional Dealmaking

Biotechs' drive to retain a bigger chunk of downstream rights is forcing product-hungry Big Pharma to accept non-global licensing deals. They'll be up against existing regional players, more accustomed to sharing rights and prioritizing others' drugs.

The Rise of Regional Dealmaking

Biotechs' drive to retain a bigger chunk of downstream rights is forcing product-hungry Big Pharma to accept non-global licensing deals. They'll be up against existing regional players, more accustomed to sharing rights and prioritizing others' drugs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel